Leanne T. Labriola
Research Subjects
Research Interests
Leanne T. Labriola has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Kathleen Campbell Garwood
Department of Decision and System Sciences, Saint Joseph’s University, Philadelphia, PA 19131, USA
6 shared publications - Kyla Frenia
Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA 15260, USA
5 shared publications - Jeremy Kimmel
Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, PA 15260, USA
4 shared publications - Kunhong Xiao
Department of Biomedical Engineering, College of Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA
4 shared publications - Maria A. Beatty
Pittsburgh Research Institute, Sewickley, PA 15143, USA
3 shared publications - David L. Bartlett
Allegheny Health Network Cancer Institute, Pittsburgh, PA 15212, USA
2 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (9) , 866
Comparative Evaluation of Traditional and Emerging Glycemic Biomarkers in Diabetes
Diabetes mellitus is a worldwide metabolic disorder that can be debilitating to many if uncontrolled. Biomarkers, such as hemoglobin A1C and glycated albumin, are central to the effort to control diabetes. These each have their own advantages and disadvantages, and there is much ongoing research into development of improved biomarkers and biomarker measurement methods. Continuous glucose monitoring is also widely used to closely monitor diabetes in patients today. Increasingly, however, there has been research focusing on the use of biomarkers in alternative mediums, such as tear fluid or saliva. This review efficiently summarizes the current biomarkers used clinically today, their advantages and disadvantages, and the biomarkers on the horizon that could advance how diabetes is treated in the future.
- 26 August 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (9) , 866
Open AccessComparative Evaluation of Traditional and Emerging Glycemic Biomarkers in Diabetes
Diabetes mellitus is a worldwide metabolic disorder that can be debilitating to many if uncontrolled. Biomarkers, such as hemoglobin A1C and glycated albumin, are central to the effort to control diabetes. These each have their own advantages and disadvantages, and there is much ongoing research into development of improved biomarkers and biomarker measurement methods. Continuous glucose monitoring is also widely used to closely monitor diabetes in patients today. Increasingly, however, there has been research focusing on the use of biomarkers in alternative mediums, such as tear fluid or saliva. This review efficiently summarizes the current biomarkers used clinically today, their advantages and disadvantages, and the biomarkers on the horizon that could advance how diabetes is treated in the future.
- Open Access
- 12 August 2026
- Published by MDPI AG in Preprints.org
Comparative Evaluation of Traditional and Emerging Glycemic Biomarkers in Diabetes
Diabetes mellitus is a worldwide metabolic disorder that can be debilitating to many if uncontrolled. Biomarkers, such as hemoglobin A1C and glycated albumin, are central to the effort to control diabetes. These each have their own advantages and disadvantages, and there is much ongoing research into development of improved biomarkers and biomarker measurement methods. Continuous glucose monitoring is also widely used to closely monitor diabetes in patients today. Increasing, however, there has been research into use of biomarkers in alternative mediums, such as tear fluid or saliva. This review efficiently summarizes the current biomarkers used clinically today, their advantages and disadvantages, as well as the biomarkers on the horizon that could advance how diabetes is treated in the future.
- 12 August 2026
- Published by MDPI AG in Preprints.org
Open AccessComparative Evaluation of Traditional and Emerging Glycemic Biomarkers in Diabetes
Diabetes mellitus is a worldwide metabolic disorder that can be debilitating to many if uncontrolled. Biomarkers, such as hemoglobin A1C and glycated albumin, are central to the effort to control diabetes. These each have their own advantages and disadvantages, and there is much ongoing research into development of improved biomarkers and biomarker measurement methods. Continuous glucose monitoring is also widely used to closely monitor diabetes in patients today. Increasing, however, there has been research into use of biomarkers in alternative mediums, such as tear fluid or saliva. This review efficiently summarizes the current biomarkers used clinically today, their advantages and disadvantages, as well as the biomarkers on the horizon that could advance how diabetes is treated in the future.
- Open Access
- 3 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8556
Translating Biomarker Discovery: From Bench to Bedside in Dry Eye Disease
Dry Eye Disease (DED) is a complex, multifaceted ocular disease characterized by tear film instability and inflammation. It can sometimes be elusive to identify the type of DED in patients, given the overlapping symptoms with other conditions like allergies and the multitude of stimuli that might trigger DED onset. There is also difficulty due to limitations on the diagnostic testing available to clinicians, as poor reliability and a lack of standardization plague accurate diagnoses. Identified biomarkers can help identify DED pathophysiology and category, and these include molecular biomarkers like matrix metalloproteinase-9 (MMP-9), cytokines, lactotransferrin, and lacritin, as well as functional biomarkers such as tear osmolarity. Diagnostic tools, such as the InflammaDry and I-Pen Tear Osmolarity System, also now allow for point-of-care measurement of select biomarkers, including MMP-9 and osmolarity. Nonetheless, there remains a critical need for additional, reliable, and accurate diagnostic devices to better aid in the diagnosis and management of DED. This review uniquely combines a review on the current understanding of various biomarkers with an overview of the emerging technologies available to healthcare providers, aiding in better-informed diagnosis and treatment of DED.
- 3 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8556
Open AccessTranslating Biomarker Discovery: From Bench to Bedside in Dry Eye Disease
Dry Eye Disease (DED) is a complex, multifaceted ocular disease characterized by tear film instability and inflammation. It can sometimes be elusive to identify the type of DED in patients, given the overlapping symptoms with other conditions like allergies and the multitude of stimuli that might trigger DED onset. There is also difficulty due to limitations on the diagnostic testing available to clinicians, as poor reliability and a lack of standardization plague accurate diagnoses. Identified biomarkers can help identify DED pathophysiology and category, and these include molecular biomarkers like matrix metalloproteinase-9 (MMP-9), cytokines, lactotransferrin, and lacritin, as well as functional biomarkers such as tear osmolarity. Diagnostic tools, such as the InflammaDry and I-Pen Tear Osmolarity System, also now allow for point-of-care measurement of select biomarkers, including MMP-9 and osmolarity. Nonetheless, there remains a critical need for additional, reliable, and accurate diagnostic devices to better aid in the diagnosis and management of DED. This review uniquely combines a review on the current understanding of various biomarkers with an overview of the emerging technologies available to healthcare providers, aiding in better-informed diagnosis and treatment of DED.
- Open Access
- 6 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 386
Precision in Tear Fluid Biomarker Discovery: Quantitative Proteomic Profiling of Small-Volume, Individual Samples Using Capillary Tube Collection
Background: Tear fluid, rich in proteins, is a promising source of novel biomarkers for ocular and systemic health. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the primary method for biomarker discovery. Still, factors such as limited sample volume, extracellular protein contamination, and reflex tearing can significantly impact results. Glass microcapillary tubes minimize these issues. Schirmer strips remain the most common collection method due to existing LC-MS/MS protocol optimization. Methods: In this study, we evaluated multiple digestion protocols for the shotgun quantitative LC-MS/MS analysis of small-volume tear fluid samples collected using glass capillary tubes. Protocol optimization was performed using pooled samples and then compared with the analysis of individual samples. Results: Using the optimized protocol, one μL samples were processed using a timsTOF Pro 2 mass spectrometer (Bruker) coupled online with an Evosep One liquid chromatography system (Evosep), leading to the identification of an average of 361 ± 63 proteins in pooled samples and 525 ± 123 proteins in individual small-volume tear fluid samples. Conclusions: This protocol highlights the practicality of using glass capillary tubes for comprehensive LC-MS/MS-based tear proteomics analysis, paving the way for detailed proteomics characterization of individual tear fluid samples rather than pooled samples. By shifting from pooled to individual samples, this approach greatly accelerates tear biomarker discovery, advancing precision and personalized medicine.
- 6 February 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 386
Open AccessPrecision in Tear Fluid Biomarker Discovery: Quantitative Proteomic Profiling of Small-Volume, Individual Samples Using Capillary Tube Collection
Background: Tear fluid, rich in proteins, is a promising source of novel biomarkers for ocular and systemic health. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the primary method for biomarker discovery. Still, factors such as limited sample volume, extracellular protein contamination, and reflex tearing can significantly impact results. Glass microcapillary tubes minimize these issues. Schirmer strips remain the most common collection method due to existing LC-MS/MS protocol optimization. Methods: In this study, we evaluated multiple digestion protocols for the shotgun quantitative LC-MS/MS analysis of small-volume tear fluid samples collected using glass capillary tubes. Protocol optimization was performed using pooled samples and then compared with the analysis of individual samples. Results: Using the optimized protocol, one μL samples were processed using a timsTOF Pro 2 mass spectrometer (Bruker) coupled online with an Evosep One liquid chromatography system (Evosep), leading to the identification of an average of 361 ± 63 proteins in pooled samples and 525 ± 123 proteins in individual small-volume tear fluid samples. Conclusions: This protocol highlights the practicality of using glass capillary tubes for comprehensive LC-MS/MS-based tear proteomics analysis, paving the way for detailed proteomics characterization of individual tear fluid samples rather than pooled samples. By shifting from pooled to individual samples, this approach greatly accelerates tear biomarker discovery, advancing precision and personalized medicine.
- Open Access
- 26 December 2024
- Published by MDPI AG in Preprints.org
Precision in Tear Fluid Biomarker Discovery: Quantitative Proteomic Profiling of Small-Volume, Individual Samples Using Capillary Tube Collection
Background/Objectives: Tear fluid, a complex biofluid that contains thousands of proteins and can be collected non-invasively, has emerged as a promising source of biomarkers for ocular and systemic health. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is currently the primary method for discovering novel biomarkers in tear fluid. However, the method of tear collection can significantly impact LC-MS/MS analysis outcomes. Tear fluid is commonly collected using either Schirmer strips or capillary tubes. While capillary tubes offer distinct advantages, such as reduced extracellular contamination and reflex tearing, most LC-MS/MS protocol development has focused on optimizing protocols for Schirmer strips. This study addresses this gap by evaluating digestion protocols for tear fluid collected with capillary tubes, focusing on biomarker discovery using small-volume samples. In this study, we evaluated multiple digestion protocols for the shotgun quantitative LC-MS/MS analysis of small-volume tear fluid samples collected using glass capillary tubes. Protocol optimization was performed using pooled samples and then compared with the analysis of individual samples. With the optimized protocol, we identified an average of 368 ± 87 proteins in pooled samples and 502 ± 127 proteins in individual small-volume tear fluid samples, using less than 1µL of total fluid volume. This protocol highlights the practicality of using glass capillary tubes for comprehensive LC-MS/MS-based tear proteomics analysis, paving the way for detailed proteomics characterization of individual tear fluid samples rather than pooled samples. By shifting from pooled to individual samples, this approach greatly accelerates tear biomarker discovery, advancing precision and personalized medicine.
- 26 December 2024
- Published by MDPI AG in Preprints.org
Open AccessPrecision in Tear Fluid Biomarker Discovery: Quantitative Proteomic Profiling of Small-Volume, Individual Samples Using Capillary Tube Collection
Background/Objectives: Tear fluid, a complex biofluid that contains thousands of proteins and can be collected non-invasively, has emerged as a promising source of biomarkers for ocular and systemic health. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is currently the primary method for discovering novel biomarkers in tear fluid. However, the method of tear collection can significantly impact LC-MS/MS analysis outcomes. Tear fluid is commonly collected using either Schirmer strips or capillary tubes. While capillary tubes offer distinct advantages, such as reduced extracellular contamination and reflex tearing, most LC-MS/MS protocol development has focused on optimizing protocols for Schirmer strips. This study addresses this gap by evaluating digestion protocols for tear fluid collected with capillary tubes, focusing on biomarker discovery using small-volume samples. In this study, we evaluated multiple digestion protocols for the shotgun quantitative LC-MS/MS analysis of small-volume tear fluid samples collected using glass capillary tubes. Protocol optimization was performed using pooled samples and then compared with the analysis of individual samples. With the optimized protocol, we identified an average of 368 ± 87 proteins in pooled samples and 502 ± 127 proteins in individual small-volume tear fluid samples, using less than 1µL of total fluid volume. This protocol highlights the practicality of using glass capillary tubes for comprehensive LC-MS/MS-based tear proteomics analysis, paving the way for detailed proteomics characterization of individual tear fluid samples rather than pooled samples. By shifting from pooled to individual samples, this approach greatly accelerates tear biomarker discovery, advancing precision and personalized medicine.
- Open Access
- 14 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 12239
High-Throughput Tear Proteomics via In-Capillary Digestion for Biomarker Discovery
Tear fluid has emerged as a valuable resource for biomarker discovery; however, the limited sample volume, the dynamic composition, and the variability introduced by collection methods all present significant challenges to the analysis and interpretation of the results. A majority of tear proteomic studies have utilized Schirmer strips for tear fluid collection; however, microcapillary collection can provide a superior collection method for proteomic studies when analysis procedures are optimized. We developed a novel, high-throughput in-capillary trypsin digestion workflow that requires as little as 0.5 μL of tear fluid for bottom–up shotgun proteomics. The use of a single microcentrifuge tube for both tear collection and sample processing simplifies sample handling and minimizes both the sample loss and experimental errors associated with sample transfers. This streamlined approach also reduces sample processing time to under 2 h before overnight trypsin digestion, compared to the 5–8 h required by the other methods. Our method uses liquid chromatography–tandem mass spectrometry (LC–MS/MS) to identify more proteins with greater efficiency than the existing techniques. With this workflow, we identified 500–800 proteins per 0.5 μL sample without peptide fractionation, allowing for at least three technical replicates. The results showed a four-fold increase in the number of proteins identified in the samples. This approach validates the use of microcapillary tear collection, and the innovative processing technique significantly increases the throughput of tear proteomics for biomarker discovery.
- 14 November 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 12239
Open AccessHigh-Throughput Tear Proteomics via In-Capillary Digestion for Biomarker Discovery
Tear fluid has emerged as a valuable resource for biomarker discovery; however, the limited sample volume, the dynamic composition, and the variability introduced by collection methods all present significant challenges to the analysis and interpretation of the results. A majority of tear proteomic studies have utilized Schirmer strips for tear fluid collection; however, microcapillary collection can provide a superior collection method for proteomic studies when analysis procedures are optimized. We developed a novel, high-throughput in-capillary trypsin digestion workflow that requires as little as 0.5 μL of tear fluid for bottom–up shotgun proteomics. The use of a single microcentrifuge tube for both tear collection and sample processing simplifies sample handling and minimizes both the sample loss and experimental errors associated with sample transfers. This streamlined approach also reduces sample processing time to under 2 h before overnight trypsin digestion, compared to the 5–8 h required by the other methods. Our method uses liquid chromatography–tandem mass spectrometry (LC–MS/MS) to identify more proteins with greater efficiency than the existing techniques. With this workflow, we identified 500–800 proteins per 0.5 μL sample without peptide fractionation, allowing for at least three technical replicates. The results showed a four-fold increase in the number of proteins identified in the samples. This approach validates the use of microcapillary tear collection, and the innovative processing technique significantly increases the throughput of tear proteomics for biomarker discovery.
- Open Access
- 8 October 2024
- Published by MDPI AG in Preprints.org
Rapid Tear Proteomics via In-Capillary Digestion for Biomarker Discovery
Tear fluid is emerging as a valuable resource for biomarker discovery, but its low sample volume and dynamic composition pose significant challenges for analytical testing. Most tear proteomics studies have focused on samples collected with Schirmer strips, while capillary tube collection has received less attention. To address these challenges, we developed a novel in-capillary trypsin digestion workflow that requires as little as 0.5 μL of tear fluid for bottom-up shotgun proteomics. This method uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify a higher number of proteins with enhanced efficiency compared to previously reported methods, which typically required 5-10 μL of pooled tear fluid. Using the same microcentrifuge tube for both tear collection and sample processing, this streamlined workflow simplifies sample handling and minimizes both sample loss and experimental errors associated with sample transfer. This method also efficiently reduced sample processing time to under 2 hours prior to overnight trypsin digestion, compared to the 5-8 hours required by other methods. With this workflow, we identified 500-800 proteins per 0.5 μL sample without the need for fractionation, allowing for at least three technical replicates. This optimized workflow greatly enhances the efficiency of tear proteomics for biomarker discovery.
- 8 October 2024
- Published by MDPI AG in Preprints.org
Open AccessRapid Tear Proteomics via In-Capillary Digestion for Biomarker Discovery
Tear fluid is emerging as a valuable resource for biomarker discovery, but its low sample volume and dynamic composition pose significant challenges for analytical testing. Most tear proteomics studies have focused on samples collected with Schirmer strips, while capillary tube collection has received less attention. To address these challenges, we developed a novel in-capillary trypsin digestion workflow that requires as little as 0.5 μL of tear fluid for bottom-up shotgun proteomics. This method uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify a higher number of proteins with enhanced efficiency compared to previously reported methods, which typically required 5-10 μL of pooled tear fluid. Using the same microcentrifuge tube for both tear collection and sample processing, this streamlined workflow simplifies sample handling and minimizes both sample loss and experimental errors associated with sample transfer. This method also efficiently reduced sample processing time to under 2 hours prior to overnight trypsin digestion, compared to the 5-8 hours required by other methods. With this workflow, we identified 500-800 proteins per 0.5 μL sample without the need for fractionation, allowing for at least three technical replicates. This optimized workflow greatly enhances the efficiency of tear proteomics for biomarker discovery.
- 12 October 2023
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 7 (6) , 510-520
Use of Adjunctive Corticosteroid With Antivascular Endothelial Growth Factor Agents in the Treatment of Choroidal Neovascular Membrane Associated With Presumed Ocular Histoplasmosis
Purpose: To evaluate the impact of combination treatment of antivascular endothelial growth factor (anti-VEGF) intravitreal injections and corticosteroids in patients with choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis syndrome (POHS). Methods: A retrospective multicenter study was conducted in a cohort from Illinois and Missouri. Patients were identified over an 8-year period, and data were evaluated over a 1-year study window commencing with treatment initiation. Group 1 included patients treated with intravitreal injections of anti-VEGF, and group 2 included those who received intravitreal injections of anti-VEGF and adjuvant corticosteroids. Optical coherence tomography (OCT) measurements and increases in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score were compared between each group. Results: Using the method of last visit carried forward, the visual acuity (VA) in group 2 was 6.42 ETDRS letters better than the VA in group 1 at the final assessment. Patients in group 2 had a mean ETDRS letter gain of 21.50 ( P = .06) from the initial baseline vision. The average amount of decrease in OCT central subfield thickness compared with baseline was lower in group 1 (80.9 ± 129.8 µm) vs group 2 (102.8 ± 90.40 µm) at the 1-year follow-up visit ( P = .25). Conclusions: Approved treatment of CNV secondary to POHS is limited. Adjuvant corticosteroid treatment in patients with CNV secondary to POHS may provide better long-term vision and OCT outcomes than anti-VEGF alone and may offer an additional therapy option for these patients.
- 12 October 2023
- Published by SAGE Publications in Journal of Vitreoretinal Diseases
- Vol. 7 (6) , 510-520
Use of Adjunctive Corticosteroid With Antivascular Endothelial Growth Factor Agents in the Treatment of Choroidal Neovascular Membrane Associated With Presumed Ocular Histoplasmosis
Purpose: To evaluate the impact of combination treatment of antivascular endothelial growth factor (anti-VEGF) intravitreal injections and corticosteroids in patients with choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis syndrome (POHS). Methods: A retrospective multicenter study was conducted in a cohort from Illinois and Missouri. Patients were identified over an 8-year period, and data were evaluated over a 1-year study window commencing with treatment initiation. Group 1 included patients treated with intravitreal injections of anti-VEGF, and group 2 included those who received intravitreal injections of anti-VEGF and adjuvant corticosteroids. Optical coherence tomography (OCT) measurements and increases in Early Treatment Diabetic Retinopathy Study (ETDRS) letter score were compared between each group. Results: Using the method of last visit carried forward, the visual acuity (VA) in group 2 was 6.42 ETDRS letters better than the VA in group 1 at the final assessment. Patients in group 2 had a mean ETDRS letter gain of 21.50 ( P = .06) from the initial baseline vision. The average amount of decrease in OCT central subfield thickness compared with baseline was lower in group 1 (80.9 ± 129.8 µm) vs group 2 (102.8 ± 90.40 µm) at the 1-year follow-up visit ( P = .25). Conclusions: Approved treatment of CNV secondary to POHS is limited. Adjuvant corticosteroid treatment in patients with CNV secondary to POHS may provide better long-term vision and OCT outcomes than anti-VEGF alone and may offer an additional therapy option for these patients.